Clinical Trial Update: An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients [Phase 4]

View source ↗

Summary

Phase IV multicenter Indian study evaluating the safety of crizanlizumab in sickle cell disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Crizanlizumab (Adakveo) (crizanlizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease (SCD) | Phase 4 | Status: COMPLETED | Results posted: 2025-01-08